T Christopher Mast

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Measuring quality of life among HIV-infected women using a culturally adapted questionnaire in Rakai district, Uganda
    T C Mast
    Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, MD, Baltimore, USA
    AIDS Care 16:81-94. 2004
  2. ncbi Epidemiology and economic burden of rotavirus gastroenteritis in hospitals and paediatric clinics in Taiwan, 2005-2006
    T Christopher Mast
    Merck and Co, Inc, PO Box 1000, North Wales, PA 19486, USA
    Vaccine 28:3008-13. 2010
  3. ncbi Burden of childhood rotavirus disease on health systems in the United States
    T Christopher Mast
    Merck Research Laboratories, North Wales, PA 19486, USA
    Pediatr Infect Dis J 29:e19-25. 2010
  4. ncbi Development and psychometric properties of the HPV Impact Profile (HIP) to assess the psychosocial burden of HPV
    T Christopher Mast
    Merck Research Laboratories, West Point, PA, USA
    Curr Med Res Opin 25:2609-19. 2009
  5. ncbi The impact of rotavirus gastroenteritis on the family
    T Christopher Mast
    Merck Research Laboratories, North Wales, PA, USA
    BMC Pediatr 9:11. 2009
  6. ncbi Immunisation coverage among children born to HIV-infected women in Rakai district, Uganda: Effect of voluntary testing and counselling (VCT)
    T C Mast
    Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
    AIDS Care 18:755-63. 2006
  7. ncbi Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua
    T Christopher Mast
    Merck Research Laboratories, North Wales, PA 19486, USA
    Pediatr Infect Dis J 30:e209-15. 2011
  8. ncbi International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials
    T Christopher Mast
    Merck Research Laboratories, West Point, PA, USA christopher
    Vaccine 28:950-7. 2010
  9. ncbi Long-term safety from the raltegravir clinical development program
    Hedy Teppler
    Hedy Teppler, MD, Merck Research Laboratories, PO Box 1000, UG3D 56, North Wales, PA 19454 1099, USA
    Curr HIV Res 9:40-53. 2011
  10. ncbi Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalizations and deaths in six Asian countries
    Antoine C El Khoury
    Merck and Co, Inc, West Point, PA, USA
    Hum Vaccin 7:506-10. 2011

Detail Information

Publications10

  1. ncbi Measuring quality of life among HIV-infected women using a culturally adapted questionnaire in Rakai district, Uganda
    T C Mast
    Department of International Health, Johns Hopkins University, Bloomberg School of Public Health, MD, Baltimore, USA
    AIDS Care 16:81-94. 2004
    ....
  2. ncbi Epidemiology and economic burden of rotavirus gastroenteritis in hospitals and paediatric clinics in Taiwan, 2005-2006
    T Christopher Mast
    Merck and Co, Inc, PO Box 1000, North Wales, PA 19486, USA
    Vaccine 28:3008-13. 2010
    ..3 days per paediatric clinic visit. These data show that rotavirus was associated with a substantial proportion of AGE medical visits and had considerable medical costs prior to rotavirus vaccine introduction...
  3. ncbi Burden of childhood rotavirus disease on health systems in the United States
    T Christopher Mast
    Merck Research Laboratories, North Wales, PA 19486, USA
    Pediatr Infect Dis J 29:e19-25. 2010
    ..To determine the burden of rotavirus disease before the introduction of rotavirus vaccines...
  4. ncbi Development and psychometric properties of the HPV Impact Profile (HIP) to assess the psychosocial burden of HPV
    T Christopher Mast
    Merck Research Laboratories, West Point, PA, USA
    Curr Med Res Opin 25:2609-19. 2009
    ..The HPV Impact Profile (HIP) was developed to determine the psychosocial impact of HPV infection and related interventions...
  5. ncbi The impact of rotavirus gastroenteritis on the family
    T Christopher Mast
    Merck Research Laboratories, North Wales, PA, USA
    BMC Pediatr 9:11. 2009
    ....
  6. ncbi Immunisation coverage among children born to HIV-infected women in Rakai district, Uganda: Effect of voluntary testing and counselling (VCT)
    T C Mast
    Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
    AIDS Care 18:755-63. 2006
    ..HIV VCT programmes should encourage HIV-infected mothers to complete childhood Immunisation. Improving access to Immunisation services could benefit vulnerable populations such as children born to HIV-infected mothers...
  7. ncbi Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua
    T Christopher Mast
    Merck Research Laboratories, North Wales, PA 19486, USA
    Pediatr Infect Dis J 30:e209-15. 2011
    ..partnered with the Nicaraguan Ministry of Health to demonstrate the public health impact of routine universal vaccination by delivering more than 1.3 million doses of the oral, pentavalent rotavirus vaccine (RV5) in a 3-year period...
  8. ncbi International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials
    T Christopher Mast
    Merck Research Laboratories, West Point, PA, USA christopher
    Vaccine 28:950-7. 2010
    ..Coincident Ad5/6 titers were lower than either Ad5 or Ad6 titers alone. Understanding pre-existing immunity to candidate vaccine vectors may contribute to the evaluation of vaccines in international populations...
  9. ncbi Long-term safety from the raltegravir clinical development program
    Hedy Teppler
    Hedy Teppler, MD, Merck Research Laboratories, PO Box 1000, UG3D 56, North Wales, PA 19454 1099, USA
    Curr HIV Res 9:40-53. 2011
    ..This manuscript provides a review of the raltegravir safety profile using data from these and other studies in the clinical development program...
  10. ncbi Projecting the effectiveness of RotaTeq® against rotavirus-related hospitalizations and deaths in six Asian countries
    Antoine C El Khoury
    Merck and Co, Inc, West Point, PA, USA
    Hum Vaccin 7:506-10. 2011
    ....